We studied 346 patients after bone marrow transplantation (BMT) for chronic myeloid leukemia (CML) for the presence of the bcr-ab/ transcript detected by the polymerase chain reaction (PCR) t o understand the frequency and implication of a positive test. A total of 634 samples of BM andlor peripheral blood were obtained for PCR analysis between 3 and 192 months after BMT. A positive PCR test at 3 months post-BMT was not statistically significantly associated with an increased risk of relapse compared with PCR-negative patients. However, a positive PCR assay at 6 months and beyond was highly associated with subsequent relapse. The Kaplan-Meier estimate of relapse for patients testing PCRpositive at 6 t o 12 months was 4290 versus 3% for PCRnegative patients (P C .0001). The Kaplan-Meier estimate of survival at 4 years for the PCR-positive patients was 74% compared with 8340 for the PCR-negative group (P = .002).
6 to 12 months post-BMT, the type of BMT donor (allogeneic matched donor Y mismatched or unrelated), and the prescence of acute GVHD were independent risk factors for subsequent relapse. The relative risk (RR) for relapse for patients PCR-positive at 6 t o 12 months post-BMT was 26.1 (95% confidence interval, 8.9 t o 76.1, P < .0001). The outcome of long-term patients (>36 months post-BMT) who tested PCRpositive was much better, as 15 of 59 (2540) tested positive for bcr-ab/, but only one patient relapsed. There was a 91% concordance between PCR tests of simultaneously obtained BM and peripheral blood. These analyses show that the PCR assay of the bcr-ablfusion transcript 6 t o 12 months post-BMT is an independent predictor of subsequent relapse which provides an opportunity for early therapeutic intervention. 0 1995 b y The American Society of Hematology.
Philadelphia chromosome (Ph). This technique can identify the bcr-ubl transcript at a dilution of a single Ph-positive cell in a background of IO5 to 10' normal cells. Although the PCR assay can detect the presence of the bcr-ab1 transcript with exquisite sensitivity, the association of the detection of bcr-ab1 post-BMT and relapse is uncertain."-*' Several studies have examined the association of PCR-positivity post-BMT, but the two largest studies are contradictory in conclusions. Roth et a12' studied 64 patients post-BMT and found that while PCR status early after transplant (< 100 days) did not correlate with relapse, PCR-positivity at later periods did predict relapse. Overall 37 of 64 patients had at least one positive assay, and 13 of these 37 (35%) relapsed.
When multiple samples were analyzed for each patient, those with 2 1 PCR-positive assay had a 40% probability of relapse, and those with all PCR-positive assays had 70% risk of relapse. Patients with multiple negative assays did not relapse. Although this study concludes that PCR-positivity at 6 months post-BMT is associated with relapse, the study by Miyamura et al," coincidentally also with 64 patients, suggests that PCR-positivity is not so foreboding. In their study patients were from 2 to 220 weeks from BMT. The analysis divided patients into two groups. Thirty-one patients had at least one negative PCR test, and none of these patients relapsed. In contrast, 33 patients had all PCR tests positive, yet only 7 relapsed. Moreover, 21 patients had a positive PCR assay greater than 1 year from transplant, with only two relapses.
Thus far, all studies have been too small to evaluate the PCR assay results with other variables known to influence the risk of relapse, such as the phase of disease, the type of allograft, and the presence of GVHD. Does the PCR assay have predictive power even when controlling for these factors, or does it merely recapitulate a known relapse risk? We report here on the PCR evaluation of 346 CML patients post-BMT and the estimate of risk of relapse associated with PCR-positivity for bcr-abl, controlling for other clinical variBlood, Vol 85, No 9 (May 1). 1995: pp 2632-2638 abies associated with relapse in multivariable models. We find that a positive PCR assay at 6 to 12 months post-BMT is an independent predictor of relapse after separately controlling for phase of disease, type of donor, and acute and chronic GVHD. We also note that PCR positivity is less common in patients greater than 12 months from transplant and is less strongly associated with relapse. Like allogeneic, related transplants, unrelated donor (URD) transplants are commonly PCR-positive early after transplant but, in contrast, URD patients who are PCR-positive infrequently relapse.
MATERIALS AND METHODS
Patients. All patients receiving transplants for CML at the Fred Hutchinson Cancer Research Center between 1976 and 1993 were eligible for study. The transplant protocols were approved by the Institutional Review Board. Patients were identified after BMT before their discharge home, or for patients already home, through contact with our Long-Term Follow-Up (LTFW) program. Requests were made to receive both BM and peripheral blood (PB) at 6-month intervals. The LTFU staff were unaware of the results of PCR assays. Many patients elected to have samples obtained at their yearly LTFU check at our institution. These BM and PB samples were used to perform cytogenetic evaluations and the PCR assay for the presence of bcr-ab[ mRNA.
Transplant regimen. Patients receiving transplants in chronic phase before 1990 received a conditioning regimen of cyclophosphamide (CY) 60 mgkg for 2 days (120 mgkg total) and total body irradiation (TBI) at a dose of 200 cGy for 6 days (1,200 cGy total).'
Since 1990 chronic phase patients were randomized to the above regimen versus busulfan (BU) 16 mgkg and CY 120
Accelerated-and blast-phase patients received a preparative regimen of CY 120 m a g and TB1 of 225 cGy for 7 days (1,575 cGy total).' Unrelated donor transplant recipients received a preparative regimen of CY 120 m@g and either 1,200 cGy of T B 1 if in chronic phase or 1,320 cGy if in accelerated or blast phase. All patients received GVHD prophylaxis with methotrexate and cyclosporine as previously described.M Sample preparation. RNA isolation from leukocytes from fresh BM and PB samples was performed by the acid guanidinium thiocyanate-phenol-chloroform method as previously described." Aliquots from this RNA were used for the detection of bcr-ab1 and the control g 2 microglobulin mRNA (below).
Reverse transcription (RT) PCR assay for bcr-abl. We used a two-step, "nested" RTPCR to amplify the chimeric bcr-ab1 mRNA. The nested reaction yields either a 305-bp or a 234-bp PCR product depending on the expression of bcr exon 3. One microgram of total RNA was added to a combination 50 pL RTPCR mix of 25 pmol of oligonucleotides CMLND and CMLNC, 50 mmoVL KCL, 10 mmom TRIS-HCL (pH 9.0). 0.1% Triton X-100 (Sigma, St Louis, MO), 200 pmoVL dioxynucleotides (dNTPs), 1.5 mmol/L MgClz, 1.25 U Taq polymerase (Amplitaq; Perkin Elmer Cetus, Nonvalk, CT), 10 U RNAsin, 7.5 U AMV RT (Boehringer Mannheim, Indianapolis, IN), and DEPC H20. This reaction mixture was incubated for 30 minutes at 42"C, brought to 95°C for 5 minutes, and then amplified for 40 cycles of 94°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute followed by a final elongation step at 72'C for 7 minutes, using an Omigene thermocycler (Hybaid, Ltd, Woodbridge, NJ). Five microliters of this first reaction was transferred to a 45-pL second reaction mixture containing fresh PCR ingredients of 25 pmol oligonucleotides CMLNA and CMLNB, 500 mmoVL KCl, 10 moVL TRIS-HCL (pH 9.0), 0.1% Triton X-100, 1 mmol/ L dNTPs, 1.5 mmol/L MgC12, 1.5 U Taq polymerase, and DEPC HzO. The tubes were placed into a preheated (65°C) thermocycler, and after an initial denaturation step of 95°C for 5 minutes, 40 cycles of amplification at 94°C for 30 seconds, 55°C for 1 minute, and 72°C for 1 minute followed by a final elongation step at 72°C for 7 minutes was performed. After amplification 15 pL of the final PCR product was electrophoresed through ethidium-bromide-stained 2% agarose gel and photographed.
For all PCR reactions a dilution of K562 RNA into the Phnegative cell line HL60 RNA served as a positive control. Negative controls included both a no-RNA PCR mix ("blank") and HL60 RNA. A separate amplification of p2 microglobulin was used as a control of RNA integrity and was performed as previously described.% Precautions to eliminate PCR carryover contamination included separate rooms for pre-PCR and amplification procedures, filtercontaining disposable pipette tips, and no-nucleic acid PCR reactions as negative control in all PCR amplification reactions.'* Using these precautions we had an approximately 2% incidence of false positive assays, defined as a positive PCR result in the no-RNA or HL60 RNA reactions. In these instances all samples run in the amplification "batch" (usually 10 samples) was repeated.
The nucleotide sequences of the PCR primers used in bcr-ab1 amplification were: CMLNA 5'-TGGAGCTGCAGATGCTGA-CCAACTCG-3'; CMLNB 5"ATCTCCACTGGCCACAAAATC-
Definition of positive and negative PCR assays. The PCR assays were performed without knowledge of the patient's cytogenetic results or hematologic remission status. A positive PCR test required a correct-size bcr-ab1 PCR product as well as negative "blank" and HL60 amplifications. A negative assay required the absence of a bcr-ab1 PCR product as well as no amplification of the "blank" and HL60-negative controls, successful amplification of the diluted K562-positive control, and a successful p2 microglobulin PCR amplification. If a positive or negative control did not amplify as expected, the entire panel of patient samples done in that amplification "batch" was discarded and repeated.
Definitions of outcomes and statistical methods. In this study we defined relapse by both hematologic and cytogenetic criteria. Cytogenetic relapse was defined as 2 5 metaphases positive for the Ph chromosome at any point in time or the presence of any Ph chromosomes on two successive cytogenetic evaluations at least 6 months apart. Patients were classified as being PCR-positive or -negative at the time interval of sampling. Relapse and survival rates for patients appropriately classified at the stated time intervals were estimated by the method of Kaplan and Meier.33 For the endpoint of relapse patients who died without relapse were censored at the time of death. The hazard rates of relapse and survival for patients classified as PCR-positive and PCR-negative at specific time intervals were compared using the log-rank test.'4 Multivariable analyses were performed by fitting Cox regression models and considering the data to be left truncated. This allowed the variable entry times onto study to be ac~ommodated.'~ PCR status was considered as a time-dependent covariate in these models.
If a patient had PCR results that were positive concurrently with a sample which showed hematologic or cytogenetic relapse, then such a patient was classified according to the PCR status at the last test before relapse. For example, a patient with a negative PCR assay at 6 months who at 12 months was FCR-positive for bcr-ab1 with cytogenetics positive for the Ph chromosome is regarded in this analysis as a patient who relapsed with a negative PCR assay at 6 months.
Patients were excluded from statistical analyses if (1) they had evidence of hematologic or cytogenetic relapse simultaineously to, 
RESULTS

Patient characteristics.
The clinical characteristics of the 346 patients included in these analyses are shown in Table 1 . Six hundred thirty-four samples of PB and/or BM were successfully analyzed by PCR; in 15 other samples RNA did not amplify from the PB and BM. One hundred sixty-two patients had one PCR test performed, and 184 had two or more tests performed. Eighty-two patients had their first PCR sample at 3 months post-BMT, 146 patients at 6 to 12 months, 83 patients at 12 months to 3 years, and 35 patients at greater than 3 years post-BMT. The total number of patients tested in each interval after BMT, categorized by type of donor and phase of disease, is shown in Table 2 . The median follow-up for all patients from the time of first PCR assay to either relapse or last contact is 16 months (range, 1 to 47 months).
PCR-pnsitivih~ and the risk qf srrbsequent relapse. The percentage of patients testing positive for hcr-ah1 by the PCR assay at 3 months, 6 to I2 months, > 12 months to 36 months, and >36 months, and the Kaplan-Meier estimates of relapse for those testing PCR-positive versus PCR-negative are shown in Fig 1. Thirty-two patients were subsequently excluded from these analyses because they relapsed The number of patients testing PCR-positive (numerator) and the total number of patients tested (denominator) in the s 3 months, >3 to s12 months, > l 2 to s 3 6 months, and >36 months post-BMT is shown in each cell of the table. The first three rows categorizes the patients by the type of donor; the next four rows categorizes patients by the phase of disease. Patients who had tests in more than one interval are included in the counts of each interval. .mol). The median time from PCR-positivity to relapse was 7 months (range, 1.5 to 12 months). A separate KaplanMeier estimation was performed for just the allogeneic-related transplants. Ninety-eight patients were tested, and 20 were PCR-positive. The Kaplan-Meier estimate of relapse associated with a PCR-positive test at 6 to 12 months post-BMT was 62%, compared with 3% for PCR-negative patients (P < .mol). Fifteen of 58 patients (25%) tested greater than 36 months post-BMT tested PCR-positive, and one relapsed. No PCRnegative patient relapsed. The median follow-up of these patients from their first PCR-positive test to present time is 22 months. Nine patients had their first positive PCR assay detected greater than 36 months post-BMT, and none have relapsed (Fig 3) . The latest finding of a new positive PCR assay following a previous negative PCR was at 48 months (unique patient number [UPN] 5026, Fig 3) .
We also examined the effect of serial PCR testing among 184 patients with 2 2 PCR tests. For patients with all positive PCR tests, the Kaplan-Meier estimate of relapse is 78%. For patients with all negative PCR tests, the Kaplan-Meier estimate of relapse is 3%. For patients with both PCR-positive and PCR-negative tests, the relapse estimate is 22% (P PCR-positivity in URDpatients. Because of the observation that URD BMT recipients have a lower relapse rate than < .0001).
allogeneic-related transplant recipientsz6.*' we performed a separate statistical analysis on the 96 patients receiving an URD BMT. Twelve of 28 (43%) URD patients were PCRpositive at 3 months, and 4 relapsed, compared with one relapse in the 16 PCR-negative patients (P = .lo, Fisher's exact test). Fourteen of 42 (33%) URD patients tested 6 to 12 months post-BMT were PCR-positive, and 2 relapsed, compared with no relapses in the 28 PCR-negative patients (Kaplan-Meier estimate of relapse 18% v 0%, respectively, P = .11).
Multivariable analyses of MRD and relapse. Clinical features potentially associated with relapse were added individually to PCR status at 6 or 12 months in multivariable analyses testing the association between relapse and PCR status along with various individual clinical variables ( Table  3) . These clinical variables included the HLA matching status of the donor (twin or matched v URD or mismatched), phase of disease at BMT (chronic phase v accelerated or blast phase), the presence or absence of acute (grade 2 11) and chronic GVHD after BMT, and the use of a TBI-containing preparative regimen. Because of the relatively small number of relapses, it was feasible to include only two covariates in any given model (PCR status plus one clinical variable). PCR-positivity alone was associated with a 26-fold risk of relapse. Match status and acute GVHD were independently significantly associated with relapse. Patients who received an allogeneic matched transplant had a relative risk (m) of relapse of 5.1 compared with URD or mismatched transplant recipients, and patients with acute GVHD grades 0 or I had an RR of relapse of 0.4 compared to patients with grades 2 11. However, these variables did not influence the strength of the risk associated with a PCRpositive assay in either multivariable model. The phase of disease and the chronic GVHD status did not contribute to the risk of relapse independent of a PCR-positive assay. . The same clinical variables along with the PCR status entered into a multivariable model in a step-up fashion, using all patients studied over all time intervals after transplantation. The RR of PCR-positivity was 30 ( P < .000l), and the only other variable entering the model was the HLA match (RR = 5.6, P = .016).
A separate analysis was performed on the 216 patients who received an allogeneic-related transplant in chronic phase. A step-up regression analysis was also performed in this group, with the variables of PCR and GVHD status. PCR status was the only variable that entered the model, with an RR of 18 ( P < ,0001). Neither acute nor chronic GVHD entered the model.
The correlation of blood and BM samples. PB and BM samples obtained on the same day post-BMT were evaluated on S 14 samples. Concordance between the PB and BM PCR result occurred in 468 samples (91%). Discordance with BM PCR-positivity and peripheral blood PCR-negativity occurred in 6.5% of tests, whereas a negative BM PCR assay with a positive PB assay occurred in 2.5% of tests.
DISCUSSION
Although the presence of the bcr-ab1 chimeric mRNA has been studied in CML patients previously, the predictive il. .')act of a positive PCR, especially in light of clinical variat es associated with relapse, has been unclear. Does the PCR detection of bcr-ab1 predict relapse even when controlling for factors such as GVHD and phase of disease? The present study of 346 patients allowed us to evaluate the predictive power of the PCR in light of other clinical variables as well as examine the significance of the PCR assay at different time points after BMT. We found that a single PCR assay positive for the bcr-ab1 chimeric mRNA was associated with a high risk of subsequent relapse. The PCR assay discriminated best at 6 to 12 months post-BMT, when patients who were PCR-positive experienced a 42% risk of relapse, compared with only 3% for those PCR-negative. Moreover, the PCR assay was the strongest predictor of relapse and remained highly associated with relapse in multivariable models when adjusted for other clinical variables associated with relapse in CML. In the multivariable model of all patients PCR-positivity carried an RR = 30, whereas in the subgroup of those receiving an allogeneic, matched transplant while in chronic phase, the RR = 18. In patients sampled greater than 36 months after BMT, and in URD transplants, a PCR-positive test was not strongly associated with relapse. It should be emphasized that these data do not mean that clinical variables such as phase of disease are unimportant in describing relapse risk, but instead indicate that PCR-positivity is in itself a strong independent predictor of relapse.
Our finding of a 42% Kaplan-Meier estimate of relapse in patients with PCR-positivity for bcr-ab1 at 6 to 12 months post-BMT is in agreement with the study by Roth et al. 23 Moreover, we found a similar influence of multiple PCR testing on predicting relapse, with a 78% estimate of relapse for patients with two or more positive PCR tests, a 22% risk for patients with only one positive test, and a 3% risk for patients with repetitive PCR-negative assays. However, we have chosen to emphasize the predictive power of a single test, thus avoiding potential biases associated with multiple testing, such as controlling for patients who either did not receive subsequent testing for a variety of reasons or who received testing at a different interval.
We found that IS of S8 patients who were studied greater than 36 months post-BMT had at least one PCR-positive test. Nine of these 14 had their first PCR test become positive at greater than 36 months after at least one negative PCR test (Fig 3) . However, with a median follow-up since first PCR-positivity of nearly 2 years none of these long-term patients has relapsed. These data suggest that PCR-positivity in these long-term patients is associated with a lower risk of relapse, or predicts a considerably slower tempo of relapse, than PCR-positivity at 6 to 12 months post-BMT. This interesting trend is most clearly demonstrated in Fig 1, which shows that the relapse risk associated with a PCR-positive assay steadily decreases from 42% at 6 to 12 months to less than 10% for those patients testing positive at greater than 36 months after BMT. These data suggest that CML may be a heterogeneous disease which may be more or less aggressive. Early PCR-positivity (6 or 12 months post-BMT) may delineate a group of patients with more aggressive disease in which the tempo of PCR-positivity to relapse is relatively quick. In contrast, patients who become PCR-positive late after BMT may have more indolent disease, which may relapse at a slower pace after PCR-positivity, if at all. Thus, although patients PCR-positive at 6 or 12 months the mGdian of first PCR-positive test to relapse was 7 months, for patients PCR positive at greater than 36 months post-BMT, the median follow-up from time of first PCR-positive test to last contact is 22 months. Previously the most extensive investigation of long-term CML patients was reported by Guerrasio et aI,** who tested 27 patients at greater than 36 months post-BMT. Five of those 27 patients had at least one PCR-positive test. One had no subsequent test, one had a subsequent PCR-positive assay, and the remaining three reverted to PCR-negativity. None of the five patients relapsed. These data combined with our experience suggest that PCR-positivity in long-term patients may not carry so high a risk of relapse compared with those patients testing positive sooner after BMT. Further follow-up will be important to see if these long-term PCR-positive patients are truly unlikely to relapse, or merely relapse at a slower rate than those patients with early PCR-positive tests.
We were interested in separately evaluating patients receiving an URD transplant because these patients experience relapse rates less than half of that of allogeneic, related transplants for CML.36.37 Interestingly, these patients have a similar rate of PCR-positivity to the aggregate CML group at 3 months and 6 to 12 months. The difference in the URD experience is that the Kaplan-Meier estimate of relapse associated with a positive PCR assay is relatively low, only 18%. There are few reports with which to c 'mpare this experience. Cross et ai" report on 15 URD recipients, IO of whom were PCR-positive at some time during the post-BMT course. They report only one cytogenetic relapse in this group. The low progression to relapse in PCR-positive patients parallels the low risk of relapse experienced in all URD transplants for CML, and may be related to the graft-versus-leukemia effect.&' Thus, the common occurrence of PCR-positivity early after transplantation implies that the preparative regimen frequently does not completely eliminate the leukemic cells and that the subsequent lower relapse rates in the URD recipients revolves around the itnmunomodulatory effect associated with GVHD.
Although our findings contrast with several studies which suggest that PCR-positivity after BMT is not associated with a dramatic increase of relapse risk,14.1','9.25.29 most studies, including our own, agree that persistently negative PCR assays from 6 to 12 months after BMT place the patient in a low-risk category. In our study, a negative PCR test at 6 to 12 months post-BMT was associated with only a 3% Kaplan-Meier estimate of relapse. At longer intervals from transplant, the predictive power of a negative exam was even more dramatic, as no patient with a negative test after 12 months has relapsed, with a median follow-up of 19 months. Taken together, all studies agree that a negative PCR test is associated with a very low risk of relapse. However, the implications of an early positive test are less clear. This may be caused largely by the sundry differences between studies both in variables related to therapy (eg, the composition of the cohort in regard to phases of disease, unmanipulated v T-cell-depleted marrow, preparative regimens, and immunosuppression regimen), and to PCR testing (eg, PCR test assay conditions and sensitivity, frequency and time points of testing, and rigor of cytogenetic testing).
Our study has practical implications for the study and treatment of CML patients post-BMT. First, there was a median of approximately 6 months from PCR-positivity to subsequent relapse, long enough to launch intervention trials. Therapeutic approaches include the reduction in the amount of immunosuppression given to prevent GVHD, the use of a interferon," or the administration of donor buffy coat infusions."" Secondly, the high concordance between results obtained from PB and BM shows that PB can be used for monitoring. Thirdly, the PCR test has less predictive value in long-term patients and URD recipients who may not benefit from routine testing for bcr-abl.
Recently studies using a semi-quantitative or competitive PCR assay for the bcr-abl fusion mRNA24.26 have suggested that a progressive increase in bcr-ab2 copy number can be used to identify those patients who will relapse from those who will not. Validation of these data may not improve on the predictive power of a negative PCR test but could improve the predictive power of a positive test. However, caution may be required to interpret quantitative results from center to center for reasons involving both center-specific treatment and patient population as well as methods of sampling and PCR testing.
In summary, the PCR assay appears to discriminate between patients at a very low risk of relapse and those at a higher risk of relapse. The predictive power of the PCR assay appears independent of other relapse risk factors. Our data indicate that the PCR test is of greatest predictive value when performed at 6 to 12 months after BMT in allogeneicrelated donor recipients. PCR testing makes possible early intervention to avert relapse.
